Seres Theraptc (NASDAQ: MCRB) shares gained 5.55% to end trading Tuesday at $21.48 per share - a net change of $1.13. Shares traded between $21.99 and $19.83 throughout the day.

1268954 shares of Seres Theraptc exchanged hands.

Visit Seres Theraptc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Seres Theraptc and to follow the company’s latest updates, you can visit the company’s profile page here: Seres Theraptc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by Barchart as of 4:30pm ET on the day of publication.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

Stocks To Watch in 5G Wireless Growth Wave: Jeff Kagan

Betting Against Elon Musk Has Not Been Profitable

Five Fallen Biotech Stocks We're Watching for Rebounds

Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins

Cohere Technologies Focused on 5G Fixed Wireless Access: Jeff Kagan

Arizona Sonoran Copper Raises C$35 Million, Including Strategic Investment by Rio Tinto

Market Stages Strong Thursday Rally, Though April Still on Pace To Be Worst Month in Two Years

Cytovia Therapeutics To Go Public Via $600 Million SPAC Merger